Endothelial SMAD1-MCAM axis facilitates sunitinib resistance and progression of clear cell renal cell carcinoma via LAMB1-ITGB1 signaling
Drug Resistance Updates · 2026-05 · 86 · 101388
DOI: 10.1016/j.drup.2026.101388 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-05. Verfasst von Hanzhong Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Henan Medical University, Xinxiang, Henan, China; Department of Urology, Changhai Hospital, Naval Medical University…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Drug Resistance, Neoplasm, Smad1 Protein. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Shanghai Anti-Cancer Association, National Natural Science Foundation of China.
Abstract (Originalsprache)
Clear cell renal cell carcinoma (ccRCC) is characterized by high metastatic potential and frequent resistance to conventional therapies, highlighting the need for a deeper understanding of its tumor microenvironment. Here, we integrated single-cell RNA sequencing and spatial transcriptomics from large ccRCC cohorts to map the cellular landscape of ccRCC. We identified a distinct stromal cell subpopulation, Melanoma Cell Adhesion Molecule, MCAM+ endothelial cells (MCAM+ ECs), which spatially associates with EMT-like tumor cells and promotes disease progression. Mechanistically, our findings suggest that MCAM+ ECs facilitate metastatic features via a LAMB1-ITGB1-RhoA signaling axis, contributing to epithelial-mesenchymal transition (EMT) and extracellular matrix remodeling. Furthermore, transcriptional analysis and experimental validation revealed that SMAD1 acts as a pivotal regulator of MCAM+ EC reprogramming by modulating MCAM and LAMB1 expression. To assess clinical relevance, we applied an integrative machine learning framework to develop an MCAM+ EC-based Risk Score (MERS). This model effectively stratified patients by overall survival and metastatic risk, demonstrating superior prognostic accuracy compared to standard clinicopathological features. Collectively, our study elucidates a critical tumor-stroma crosstalk mechanism governed by the SMAD1-MCAM-LAMB1-ITGB1-RhoA axis, providing novel mechanistic insights into the metastatic process and identifying potential candidates for therapeutic intervention in ccRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital of Henan Medical University, Xinxiang, Henan, China; Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China; Department of Urology, The First Naval Hospital of…
- Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
- Department of Anesthesiology, Changhai Hospital, Naval Medical University, Shanghai, China.
- Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China; Urologic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
- Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China; Donghai County People's Hospital (Affiliated Kangda College of Nanjing Medical University), Lianyungang, China.
- Department of Urology, The First Naval Hospital of Southern Theater Command, Zhanjiang, China.
Förderung
- Shanghai Anti-Cancer Association
- National Natural Science Foundation of China
Zitieren
APA
Zhang, H., Liu, Y., Zhang, W., Guo, Y., Lin, A., Jin, Y., Lu, P., Fang, Y., Zhang, H., Qu, L., Luo, P., Wu, L., Chen, Y., Kang, X., Wang, L., & Jiang, A. (2026). Endothelial SMAD1-MCAM axis facilitates sunitinib resistance and progression of clear cell renal cell carcinoma via LAMB1-ITGB1 signaling. Drug Resistance Updates, 86, 101388. https://doi.org/10.1016/j.drup.2026.101388
Vancouver
Zhang H, Liu Y, Zhang W, Guo Y, Lin A, Jin Y, et al. Endothelial SMAD1-MCAM axis facilitates sunitinib resistance and progression of clear cell renal cell carcinoma via LAMB1-ITGB1 signaling. Drug Resistance Updates. 2026;86:101388. doi:10.1016/j.drup.2026.101388
BibTeX
@article{Zhang2026,
author = {Zhang, Hanzhong and Liu, Ying and Zhang, Wangzheqi and Guo, Yadong and Lin, Anqi and Jin, Yuming and Lu, Ping and Fang, Yu and Zhang, Haoling and Qu, Le and Luo, Peng and Wu, Lingfeng and Chen, Yinghu and Kang, Xiaohong and Wang, Linhui and Jiang, Aimin},
title = {Endothelial SMAD1-MCAM axis facilitates sunitinib resistance and progression of clear cell renal cell carcinoma via LAMB1-ITGB1 signaling},
journal = {Drug Resistance Updates},
year = {2026},
volume = {86},
pages = {101388},
doi = {10.1016/j.drup.2026.101388}
}
EUVIMED